bioAffinity Technologies (BIAF) vs MDxHealth SA (MDXH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MDxHealth SA is the larger company by market cap ($56.3 million vs $5.5 million), about 10.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIAF | MDXH |
|---|---|---|
| Share price | $4.73 | $0.5897 |
| Market cap | $5.51M | $56.27M |
| 1-day change | -16.22% | +1.58% |
| YTD return | — | -83.48% |
| 1-year return | — | -86.47% |
| EPS (TTM) | $-91.61 | $-0.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $80.70 | $5.33 |
| 52-week low | $4.56 | $0.40 |
| Distance from 52-week high | -94.14% | -88.94% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +205.24% |
| Average volume | 3.73M | 5.78M |
| Shares outstanding | 1.17M | 95.42M |
| Employees | 57 | 364 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MDxHealth SA is about 10.2 times larger than bioAffinity Technologies by market value ($56.27M vs $5.51M).
About bioAffinity Technologies
BIAF stock →bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 57 employees
About MDxHealth SA
MDXH stock →MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
Health Care · Medical Specialities · 364 employees
BIAF vs MDXH FAQ
Which is bigger, bioAffinity Technologies or MDxHealth SA?
MDxHealth SA (MDXH) is larger, with a market capitalization of $56.27M compared with $5.51M for bioAffinity Technologies (BIAF).
Are bioAffinity Technologies and MDxHealth SA in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Commercial Physical & Biological Resarch for bioAffinity Technologies and Medical Specialities for MDxHealth SA.